D.E. Shaw & Co
OBIO icon

D.E. Shaw & Co’s Orchestra BioMed OBIO Stock Holding History

D.E. Shaw & Co’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-938,388
Closed -$9.35M – 5423
2022
Q2 		$9.35M Buy
938,388
+51,487
+6% +$512K 0.01% 1451
2022
Q1 		$8.79M Buy
886,901
+108,119
+14% +$1.07M 0.01% 1719
2021
Q4 		$7.79M Buy
778,782
+526,264
+208% +$5.19M 0.01% 1917
2021
Q3 		$2.5M Buy
252,518
+222,717
+747% +$2.2M ﹤0.01% 2829
2021
Q2 		$304K Buy
+29,801
New +$308K ﹤0.01% 4272

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

D.E. Shaw & Co's OBIO Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 938,388 shares — an estimated $9.35M sold.

D.E. Shaw & Co first reported a position in OBIO in Q2 2021 and held it in 5 quarters. The position peaked at $9.35M in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 938,388 Orchestra BioMed shares in Q3 2022, an estimated $9.35M.
  • D.E. Shaw & Co first reported a position in Orchestra BioMed in Q2 2021 and held it in 5 quarters.
  • D.E. Shaw & Co's Orchestra BioMed position peaked at $9.35M in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.